Univest
Univest
  • Markets

Global Health Q4 FY26 Results: PAT of Rs 143.98 crore (up 41.97% YoY) Multi-Specialty Hospitals

  • May 15, 2026
  • Posted by: Neeraj Pandey
  • Category: News
No Comments
Global Health Q4 FY26 Results

Global Health Q4 results were announced on May 14, 2026, at the company’s board meeting. Global Health Limited (Medanta Hospitals) Q4 FY26 PAT rose 41.97% YoY to Rs 143.98 crore from Rs 101.40 crore in Q4 FY25. FY26 total income Rs 4,157 crore (up from Rs 3,771 crore in FY25). FY26 PAT significantly higher than FY25’s Rs 481.44 crore. Medanta operates hospitals in Gurugram, Lucknow, Patna, Ranchi, Indore, Noida, and Dubai, with 4,000+ beds and 35+ specialties. Investors tracking the company will find complete financial data, analysis, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Global Health Q4 FY26 Key Financial Highlights
  • Global Health Performance Analysis
  • Global Health FY27 Outlook
  • Frequently Asked Questions on Global Health Q4 FY26 Results
    • What is Global Health Q4 FY26 PAT?
    • When did Global Health announce Q4 FY26 results?
    • What is the FY27 outlook for Global Health?
    • Where can I track Global Health Q4 FY26 live data?

Global Health Q4 FY26 Key Financial Highlights

Metric Q4 FY26 Comparison
PAT (Net Profit) Rs 143.98 crore Q4 FY25 / Reference | up 41.97% YoY from Rs 101.40 crore
Ticker MEDANTA Sector: Multi-Specialty Hospitals

Screen the best stocks on the Univest Screener.

Global Health Performance Analysis

The company results reflect the company’s operational performance during the January to March 2026 quarter. Global Health Limited (Medanta Hospitals) Q4 FY26 PAT rose 41.97% YoY to Rs 143.98 crore from Rs 101.40 crore in Q4 FY25. FY26 total income Rs 4,157 crore (up from Rs 3,771 crore in FY25) Investors and analysts monitoring the company results will focus on FY27 revenue guidance, margin trajectory, and management commentary on business outlook.

The company performance positions the company for FY27. Track the company analyst ratings and live stock price on the Univest Screener for real-time investment insights.

Global Health FY27 Outlook

Post Global, investor focus for FY27 will be on revenue growth momentum, margin expansion, new order wins, and sector-specific tailwinds in the Multi-Specialty Hospitals space. The Global results demonstrate the company’s execution capabilities. Track Global updates on the Univest Screener for analyst views and FY27 earnings estimates.

Download the Univest iOS App or the Univest Android App to track live price and Q4 FY26 earnings updates.

Frequently Asked Questions on Global Health Q4 FY26 Results

What is Global Health Q4 FY26 PAT?

Ans. Global Health Q4 FY26 profit after tax was Rs 143.98 crore, up 41.97% YoY from Rs 101.40 crore in Q4 FY25..

When did Global Health announce Q4 FY26 results?

Ans. the company results were announced on May 14, 2026, at the company’s board meeting and filed with BSE and NSE.

What is the FY27 outlook for Global Health?

Ans. Post the company results, investors will track FY27 guidance and growth strategies in the Multi-Specialty Hospitals sector. Track live updates on the Univest Screener.

Where can I track Global Health Q4 FY26 live data?

Ans. Track the company live stock price, analyst ratings, and earnings updates on the Univest Screener for real-time investment data.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered advisor before making any investment decision.



News Q4 Results
Author: Neeraj Pandey
Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply